Andrew Gengos has been named chief operating officer and head of corporate development for Cambridge, MA, biotech Synlogic (NASDAQ: [[ticker:SYBX]]). Gengos was most recently president and CEO of Westlake Village, CA-based ImmunoCellular Therapeutics (NYSE MKT: [[ticker:IMUC]]). Synlogic, which genetically engineers microbes for therapeutic applications, went public earlier this year in a reverse merger.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
